Edition:
India

Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)

CRBP.OQ on NASDAQ Stock Exchange Global Market

7.05USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$7.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
108,286
52-wk High
$10.50
52-wk Low
$5.35

Latest Key Developments (Source: Significant Developments)

Corbus Pharmaceuticals Q3 loss per share $0.14
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Corbus Pharmaceuticals Holdings Inc : :Corbus Pharmaceuticals reports 2017 third quarter financial results and highlights recent corporate and clinical advancements.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.14.Corbus Pharmaceuticals Holdings Inc - ‍company expects current cash on hand to fund operations into Q4 of 2019,based on current planned expenditures​.Corbus Pharmaceuticals Holdings Inc - qtrly revenue $796,312 versus $742,558.  Full Article

Corbus Pharma reports improvement in skin conditions in a mid-stage study
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports significant improvement in mRSS and other clinical outcomes at 28-weeks in systemic sclerosis open-label extension of phase 2 study.Corbus Pharmaceuticals Holdings Inc - ‍Company on track to commence phase 3 study Q4 2017​.Corbus Pharmaceuticals Holdings Inc - Were no severe or serious adverse events and no clinically significant laboratory abnormalities related to drug​.Corbus Pharmaceuticals - "‍Our focus now is to ensure successful execution of our phase 3 study, and we are on track to commence this before year end"​.  Full Article

Corbus Pharma prices underwritten public offering of common stock
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals Holdings, Inc. prices underwritten public offering of common stock.Says public offering of 4.65 million common shares priced at $7.00 per share.  Full Article

Corbus Pharmaceuticals Holdings announces proposed public offering of common stock
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals Holdings Inc announces proposed public offering of common stock.Corbus Pharmaceuticals Holdings Inc - ‍Corbus intends to use proceeds of proposed offering to fund its continued development of anabasum, among others​.  Full Article

Corbus Pharma's inflammatory disease drug succeeds mid-stage study
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports positive topline results from phase 2 study in rare autoimmune disease dermatomyositis.Corbus Pharmaceuticals Holdings Inc - ‍Anabasum was well tolerated with no severe or serious side effects associated with drug​.Corbus Pharmaceuticals Holdings Inc - ‍Anabasum also outperformed placebo in multiple secondary efficacy outcomes studied​.  Full Article

Corbus Pharmaceuticals reports Q2 loss per share $0.11
Monday, 15 Aug 2016 

Corbus Pharmaceuticals Holdings Inc : Q2 loss per share $0.11 ." Believes it has sufficient financial resources to funds operations into Q4 of 2017".  Full Article

Corbus Pharmaceuticals reports Q1 loss per share $0.08
Monday, 16 May 2016 

Corbus Pharmaceuticals Holdings Inc : Corbus Pharmaceuticals reports 2016 first quarter financial results and provides business update . Q1 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S .Q1 loss per share $0.08.  Full Article

Corbus Pharmaceuticals Holdings Q1 loss per share $0.08
Monday, 16 May 2016 

Corbus Pharmaceuticals Holdings Inc : Quarterly loss per share $0.08 .Plans to initiate a clinical study in systemic lupus erythematosus ( SLE ) in Q1 of 2017.  Full Article

BRIEF-Corbus Pharmaceuticals Q3 loss per share $0.14

* Corbus Pharmaceuticals reports 2017 third quarter financial results and highlights recent corporate and clinical advancements